

Netherlands

Factor VIII per capita compared to other countries

This country fact sheet accompanies the EHC heat map and gives you further information on the country's progress over the various EHC surveys.

Here, you will see how the FVIII international units provision has evolved and compares to other countries. You will also find the same parameters as in the heat map.



Change since previous survey: ▲ Improvement ▼ Decline

		2009	2012	2015	2018
International units per capita	Factor VIII	0.00	0.00	0.00	0.00
	Factor IX	0.00	0.00	0.00	0.00
Organisation of care	Comprehensive Care Centres (CCC's)	Yes	Yes	Yes	Yes
	Haemophilia Treatment Centres	Yes	Yes	▼ No	No
	National Haemophilia Council or Co-ordinating Group	Yes	Yes	Yes	Yes
	Number of groups in decision-making on haemophilia care	2	▲ 3	3	3
	Number of groups choosing haemophilia treatment products	2	2	2	▼ 1
	National Tender for procurement of factor concentrates	No	No	No	▲ Yes
Treatment regimens	Home Treatment	Yes	Yes	Yes	Yes
	% of people with haemophilia using home treatment	76-100%	76-100%	76-100%	76-100%
	Treatment delivered to the patient's home	Unknown	Some	Some	Some
	Prophylaxis treatment availability	Yes	Yes	▼ Some	▲ Yes
	Children currently on prophylaxis (%)	76-100%	76-100%	76-100%	76-100%
	Adults currently on prophylaxis (%)	76-100%	▼ 51-75%	▲ 76-100%	76-100%
Access to specialist services	Access to ITI (% of people with inhibitors)	100%	▼ 76-99%	▲ 100%	100%
Access to specialist services	Emergency medicine and acute surgery	Yes	Yes	Yes	Yes
	Paediatrics	Yes	Yes	Yes	Yes
	Infectious disease specialists (especially HIV)	Yes	Yes	Yes	Yes
	Hepatology	Yes	Yes	Yes	Yes
	Rheumatology	Yes	Yes	Yes	Yes
	Orthopaedics	Yes	Yes	Yes	Yes
	Physiotherapy	Yes	▼ Sometimes	▲ Yes	Yes
	Dentistry	Sometimes	Sometimes	▲ Yes	Yes
	Obstetrics and Gynaecology	Sometimes	▲ Yes	Yes	Yes
	Genetics	Yes	Yes	Yes	Yes
	Social and psychological support	Yes	Yes	Yes	Yes
	Pain management	Sometimes	Sometimes	▲ Yes	Yes
	General surgery	Yes	Yes	Yes	Yes
Urology	Sometimes	Sometimes	▲ Yes	Yes	
Share of Expected Bleeding Disorder Prevalence	Haemophilia A		71%	▲ 76%	
	Haemophilia B		40%	▲ 62%	
	von Willebrand Disease		15%	▼ 6%	
Haemophilia replacement therapy	Plasma-derived factor concentrate	Always	Always	▼ Rarely	Rarely
	Recombinant factor concentrate	Always	Always	Always	Always
	Plasma	Never	Never	Never	Never
	Cryoprecipitate	Never	Never	Never	Never
VWD replacement therapy	Plasma-derived factor concentrate	Rarely	▲ Always	▼ Rarely	▲ Sometimes
	DDAVP	Always	Always	Always	▼ Sometimes
	Plasma	Rarely	▲ Never	Never	▼ Sometimes
	Cryoprecipitate	Never	Never		Never